We measure our impact by patient outcomes and the success of our partners. Learn More
It’s time for reality to catch up to the promise of machine learning in medicine. This means fully integrating molecular and clinical data for improved patient outcomes - in clinical trials and at the bedside. We are building the engineering layer to enact algorithms into clinical practice.
Get the right intervention, to the right patient, at the right time.
Andrew joins Dascena from Tilray, where he operated as Chief Corporate Development Officer through to the company’s announced sale for $1.4bn. During his time at Tilray, Andrew led the rapid global growth of the business, quadrupling revenue while driving the business to achieve profitability over the course of two years. Previously, Andrew was a Managing Director at Goldman Sachs, where he served as a senior leader within the investment bank’s Global Healthcare Group in New York, as well as Canadian Investment Banking franchise. Over the course of his career at Goldman Sachs, Andrew advised on more than $200 billion in M&A and financing transactions across the healthcare industry.
Steve oversees the legal function at Dascena and has over 30 years of experience in the biotech, pharma, and technology industries. Steve was most recently a co-founder and the CEO of Kota Biotherapeutics, a startup incubated at Intellectual Ventures in Bellevue, WA. Prior to Kota, Steve was Vice President, Patent Counsel of the Biomedical Group at Intellectual Ventures. Previously, he was VP, General Counsel and Head of Business Development at Ceptyr, Inc. a biotechnology company. Steve also served as the Managing Counsel for IP and Licensing at Immunex Corp, which was acquired by Amgen. Prior to Immunex, he served as a patent attorney for Hoffman La-Roche.